The Kagoshima-based company reported a net profit of ¥2.27 billion for the period, a significant drop from the ¥3.21 billion recorded during the same timeframe a year earlier. This bottom-line pressure followed a dip in consolidated revenue, which fell to ¥21.20 billion from ¥22.24 billion. The results, prepared under Japanese accounting standards, underscore a tightening operational environment for the laboratory services provider.
In section Market Quotes
Shin Nippon Biomedical Profits Slide as Nine-Month Revenue Softens
Shin Nippon Biomedical Laboratories Ltd. posted a sharp decline in its nine-month earnings through December 31, 2024, as the Japanese contract research specialist grappled with lower revenue and shrinking margins.
Eroding Operating Margins
The squeeze was more pronounced at the operational level. Operating profit tumbled to ¥1.03 billion, representing a nearly 45% decrease from the ¥1.89 billion achieved in the prior year. Despite the downturn, pretax profit remained relatively resilient at ¥3.12 billion, though it still fell short of the ¥4.14 billion posted previously, according to the company's financial statement.Investors saw a corresponding decline in shareholder returns during the nine-month window:
- Earnings per share dropped to ¥54.54, down from ¥76.99.
- Operating profit margins contracted significantly year-over-year.
- Total group revenue saw a contraction of approximately 4.7%.
Comments (0)
No comments yet. Be the first!